GlassScriptPhysician profile
Brittany Jones
NPI 1922335736
$3,914.39
in general payments reported to CMS, 2019-2025
30 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $995 · 2022: $461 · 2023: $888 · 2024: $983 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,458.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,150.22 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $599.85 | 2021-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $573.28 | 2021-2025 | Belbuca, Xtampza |
| Pfizer INC. | $353.57 | 2023-2025 | |
| Abbott Laboratories | $211.32 | 2022-2024 | Proclaim, Eterna |
| Redhill Biopharma INC. | $103.02 | 2021 | |
| Nalu Medical, INC. | $96.65 | 2024 | Nalu Neurostimulation System |
| Allergan, INC. | $86.89 | 2021-2022 | |
| Fidia Pharma USA INC. | $72.11 | 2021-2023 | Triluron, Hymovis |
| Ferring Pharmaceuticals INC. | $60.43 | 2024 | Euflexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $58.32 | 2022 | |
| Almatica Pharma LLC | $56.82 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $48.74 | 2021 | |
| Boston Scientific Corporation | $47.77 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Grt US Holding, INC. | $45.00 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $41.67 | 2021-2023 | Lucemyra, Zimhi |
| Nevro Corp. | $34.50 | 2021-2022 | |
| Depuy Synthes Sales INC. | $32.00 | 2023-2024 | Orthovisc, Monovisc |
| Virtus Pharmaceuticals LLC | $29.61 | 2021 | |
| Medtronic, INC. | $28.22 | 2025 | Inceptiv |
| Glaxosmithkline, LLC. | $24.89 | 2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Biotronik Nro, INC. | $23.81 | 2025 | Prospera |
| Scilex Pharmaceuticals INC. | $23.77 | 2021 | |
| Lundbeck LLC | $21.62 | 2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $18.90 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $18.22 | 2025 | |
| Horizon Therapeutics Plc | $14.77 | 2021 | |
| Bioventus LLC | $14.67 | 2021 | |
| Electronic Waveform Lab, INC. | $11.88 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.